


ADDRESSING RESPIRATORY COMPROMISE. **THE PRODIGY STUDY.**

ABOUT THE STUDY¹

Prediction of **O**pioid-induced respiratory
Depression In patients monitored by capnoGraphY


- 1,495 patients enrolled, data from 1,335 patients analyzed
- Blinded Microstream™ capnography and Nellcor™ pulse oximetry data used to determine respiratory depression episodes, based on predefined criteria
- Endpoints included 3 or more continuous minutes of alarm violations for all parameters, excluding apnea



- 16 sites
- International multi-center prospective study
- Medtronic-sponsored

ABOUT THE PROBLEM

Respiratory depression is common



46% of patients receiving opioids on the general care floor experience respiratory depression¹



Respiratory depression episodes (RDEs) are costly — for both hospitals and patients

Patients with ≥ 1 RDEs were more likely to experience an adverse event (AE) that required action.¹

- Relative risk of 1.36 for AE requiring prolonged hospitalization
- Relative risk of 2.46 for AE requiring rescue, including rapid response team activation

↑ Even without serious adverse events, the mean cost for high-risk patients with respiratory depression is \$6,448 higher than for high-risk patients without RDEs.²

Mean hospital length of stay was three days longer in patients with ≥ 1 RDE.¹



ABOUT MITIGATING THE RISK

The PRODIGY Risk Prediction Tool

Validated scoring tool to help identify patients at risk for opioid-induced respiratory depression

BASED ON FIVE EASY-TO-OBTAIN VARIABLES

Age	Sex	Opioid naïve	Sleep disordered breathing	Chronic heart failure
1	2	3	4	5



1. Khanna AK, Bergese S, Jungquist CR, et al. Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: an international prospective, observational trial. *Anesth Analg*. 2020; In press.

2. Saager L, Jiang W, Khanna A, et al. Respiratory depression on general care floors increases cost of care: results from the PRODIGY trial. American Society of Anesthesiologists Abstract Publication 2019.

IMPORTANT: Please refer to the package insert for complete instructions, contraindications, warnings and precautions.

© 2020 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic.

All other brands are trademarks of a Medtronic company. 20-weu-respiratory-compromise-prodigy-study-infographics-4510726

[medtronic.co.uk/rms](https://www.medtronic.co.uk/rms)

Medtronic